SA519410563B1 - مركب بيريميدين - Google Patents
مركب بيريميدينInfo
- Publication number
- SA519410563B1 SA519410563B1 SA519410563A SA519410563A SA519410563B1 SA 519410563 B1 SA519410563 B1 SA 519410563B1 SA 519410563 A SA519410563 A SA 519410563A SA 519410563 A SA519410563 A SA 519410563A SA 519410563 B1 SA519410563 B1 SA 519410563B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- seizure
- pyrimidine compound
- formula
- diagnosing
- treating
- Prior art date
Links
- -1 Pyrimidine Compound Chemical class 0.000 title abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 6
- 208000002091 Febrile Seizures Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000028329 epileptic seizure Diseases 0.000 abstract 1
- 206010016284 febrile convulsion Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Abstract
يتعلق الاختراع الحالي بتوفير مركب بيريميدين pyrimidine جديد ممثل بواسطة الصيغة [I] وملح منه: (I) [في الصيغة، تكون الرموز على النحو المحدد في الوصف الكامل]، حيث يكون مفيد لعلاج، الوقاية من و/أو تشخيص نوبة seizure وما شابه ذلك في مرض يتضمن نوبة صرعية epileptic seizure أو نوبة تشنجية convulsive seizure (بما في ذلك نوبة مقاومة للعقاقير المتعددة multiple drug resistant seizure ، النوبة المقاومة للحرارة refractory seizure ، النوبة العرضية الحادة acute symptomatic seizure ، النوبة الحمية febrile seizure وحالة صرعية status epilepticus)، فضلاً عن استخدامه الطبي.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/020322 WO2018220762A1 (ja) | 2017-05-31 | 2017-05-31 | ピリミジン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519410563B1 true SA519410563B1 (ar) | 2022-07-25 |
Family
ID=62685028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410563A SA519410563B1 (ar) | 2017-05-31 | 2019-11-14 | مركب بيريميدين |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10800758B2 (ar) |
| EP (1) | EP3630729B1 (ar) |
| JP (1) | JP6739653B2 (ar) |
| KR (1) | KR20200011962A (ar) |
| CN (1) | CN110603248B (ar) |
| AU (1) | AU2018277949B2 (ar) |
| BR (1) | BR112019023988A2 (ar) |
| CA (1) | CA3064176A1 (ar) |
| CY (1) | CY1125073T1 (ar) |
| DK (1) | DK3630729T3 (ar) |
| EA (1) | EA038907B1 (ar) |
| ES (1) | ES2901452T3 (ar) |
| HR (1) | HRP20211913T1 (ar) |
| HU (1) | HUE056942T2 (ar) |
| IL (1) | IL270579B2 (ar) |
| LT (1) | LT3630729T (ar) |
| MX (1) | MX2019014384A (ar) |
| PH (1) | PH12019502639A1 (ar) |
| PL (1) | PL3630729T3 (ar) |
| PT (1) | PT3630729T (ar) |
| SA (1) | SA519410563B1 (ar) |
| SI (1) | SI3630729T1 (ar) |
| TW (2) | TW202346283A (ar) |
| WO (2) | WO2018220762A1 (ar) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
| EP3887358A1 (en) * | 2018-11-30 | 2021-10-06 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compounds for the treatment of epilepsy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009559A2 (en) * | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| EA019970B8 (ru) | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Производные имидазолидиндиона |
| MX2012008346A (es) * | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos. |
| BR112013013914B1 (pt) * | 2010-12-06 | 2021-10-26 | Autifony Therapeutics Limited | Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos |
| WO2012168710A1 (en) * | 2011-06-07 | 2012-12-13 | Autifony Therapeutics Limited | Hydantoin derivates as kv3 inhibitors |
| WO2013016488A1 (en) * | 2011-07-28 | 2013-01-31 | Celia Dominguez | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| KR20140098850A (ko) | 2011-12-06 | 2014-08-08 | 오티포니 세라피틱스 리미티드 | Kv3 억제제로서 유용한 하이단토인 유도체 |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
-
2017
- 2017-05-31 WO PCT/JP2017/020322 patent/WO2018220762A1/ja active Application Filing
-
2018
- 2018-05-30 TW TW112129778A patent/TW202346283A/zh unknown
- 2018-05-30 TW TW107118471A patent/TWI808974B/zh active
- 2018-05-31 US US16/471,998 patent/US10800758B2/en active Active
- 2018-05-31 MX MX2019014384A patent/MX2019014384A/es unknown
- 2018-05-31 SI SI201830499T patent/SI3630729T1/sl unknown
- 2018-05-31 JP JP2019535398A patent/JP6739653B2/ja active Active
- 2018-05-31 EP EP18732930.5A patent/EP3630729B1/en active Active
- 2018-05-31 BR BR112019023988-0A patent/BR112019023988A2/pt unknown
- 2018-05-31 HR HRP20211913TT patent/HRP20211913T1/hr unknown
- 2018-05-31 CN CN201880030366.XA patent/CN110603248B/zh active Active
- 2018-05-31 AU AU2018277949A patent/AU2018277949B2/en active Active
- 2018-05-31 PL PL18732930T patent/PL3630729T3/pl unknown
- 2018-05-31 PT PT187329305T patent/PT3630729T/pt unknown
- 2018-05-31 EA EA201992831A patent/EA038907B1/ru unknown
- 2018-05-31 HU HUE18732930A patent/HUE056942T2/hu unknown
- 2018-05-31 CA CA3064176A patent/CA3064176A1/en active Pending
- 2018-05-31 DK DK18732930.5T patent/DK3630729T3/da active
- 2018-05-31 ES ES18732930T patent/ES2901452T3/es active Active
- 2018-05-31 WO PCT/JP2018/020997 patent/WO2018221667A1/en active Application Filing
- 2018-05-31 KR KR1020197037748A patent/KR20200011962A/ko not_active Application Discontinuation
- 2018-05-31 LT LTEPPCT/JP2018/020997T patent/LT3630729T/lt unknown
-
2019
- 2019-11-12 IL IL270579A patent/IL270579B2/en unknown
- 2019-11-14 SA SA519410563A patent/SA519410563B1/ar unknown
- 2019-11-22 PH PH12019502639A patent/PH12019502639A1/en unknown
-
2020
- 2020-09-02 US US17/010,182 patent/US20200399245A1/en not_active Abandoned
-
2021
- 2021-12-13 CY CY20211101091T patent/CY1125073T1/el unknown
-
2022
- 2022-12-30 US US18/091,790 patent/US20230138411A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123353T1 (el) | Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| SG176628A1 (en) | Aminopyrrolidinone derivatives and uses thereof | |
| PH12014502396B1 (en) | Nitrogenated heterocyclic compound | |
| MX2017008417A (es) | Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1). | |
| MX2016008624A (es) | Inhibidores de serina/treonina cinasa. | |
| TN2015000514A1 (en) | 3,4-dihydroisoquinolin-2(1h)-yl compounds | |
| MX2016002367A (es) | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. | |
| MX2019008808A (es) | Compuesto de pirimidina y su uso farmaceutico. | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| SG10201900144TA (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| MX2015011180A (es) | Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc). | |
| BR112015004029A2 (pt) | Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo | |
| JO3719B1 (ar) | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 | |
| PH12019550224A1 (en) | Antitumoral compounds | |
| PH12019502639A1 (en) | Pyrimidine compound | |
| PH12021551233A1 (en) | Heterocyclic compounds for the treatment of epilepsy | |
| SG11201803867TA (en) | Sodium channel blocker | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| EA201792109A1 (ru) | Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера | |
| MX2017011087A (es) | Derivados de tetrahidropiranil benzamida. | |
| MX2019005504A (es) | Potenciadores de bmp. | |
| MX2022005914A (es) | Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina. | |
| PE20180020A1 (es) | Compuestos |